Adeofarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 5,885,328 | 4,429,483 | 4,877,050 | 7,544,591 | 7,968,469 | 8,032,395 | 13,260,178 | 24,099,602 |
| Profit before tax | 177,083 | 129,710 | 200,771 | 590,649 | 689,527 | 604,286 | 658,946 | 1,396,976 |
| Net profit | 139,639 | 110,599 | 161,403 | 497,715 | 587,807 | 511,254 | 552,468 | 1,166,945 |
| Equity | 639,938 | 670,537 | 831,940 | 1,097,031 | 1,184,838 | 1,196,092 | 1,448,560 | 2,315,505 |
| Liabilities | 497,800 | 387,896 | 447,288 | 388,636 | 423,188 | 445,514 | 795,951 | 1,135,284 |
| Non-current assets | 399,573 | 384,919 | 358,943 | 383,776 | 352,377 | 323,473 | 296,670 | 273,545 |
| Current assets | 735,898 | 668,155 | 914,441 | 1,095,506 | 1,249,060 | 1,308,660 | 1,941,257 | 3,173,790 |
| Total assets | 1,135,471 | 1,053,074 | 1,273,384 | 1,479,282 | 1,601,437 | 1,632,133 | 2,237,927 | 3,447,335 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 291,533 | 105,355 | 191,528 |
| Social insurance contributions | - | - | - | - | - | 80,978 | 105,932 | 161,170 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -19.3% | -24.7% | +10.1% | +54.7% | +5.6% | +0.8% | +65.1% | +81.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 12.3% | 10.5% | 12.7% | 33.6% | 36.7% | 31.3% | 24.7% | 33.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 21.8% | 16.5% | 19.4% | 45.4% | 49.6% | 42.7% | 38.1% | 50.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.4% | 2.5% | 3.3% | 6.6% | 7.4% | 6.4% | 4.2% | 4.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.0% | 2.9% | 4.1% | 7.8% | 8.7% | 7.5% | 5.0% | 5.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.8 | 0.6 | 0.5 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 830,874 | 492,165 | 532,040 | 823,043 | 790,264 | 1,004,049 | 1,348,497 | 1,818,838 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Adeofarma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-07-16 | 2024-07-17 | 5755.14 |
| 2022-05-17 | 2022-05-18 | 6.16 |
| 2022-04-28 | 2022-05-09 | 6.16 |
| 2022-01-18 | 2022-01-19 | 6842.65 |
Adeofarma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Adeofarma, UAB (code 303097819) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €24.10M and net profit of €1.17M, corresponding to a profit margin of 4.8%. Performance strengthened materially over the last three years: revenue rose from €8.03M in 2023 to €13.26M in 2024 and then to €24.10M in 2025, while net profit increased from €511.3K to €552.5K and then to €1.17M. The 2025 growth rates were 81.7% year on year and 200.0% over two years. The balance sheet also expanded, with total assets increasing to €3.45M, equity to €2.32M and liabilities to €1.14M. Equity represented 67.2% of assets, and debt-to-equity stood at 0.49. Operational efficiency remained strong, with asset turnover at 6.99x and revenue per employee at €1.85M. Return on equity reached 50.4% and return on assets 33.9% in 2025.